Osteoarthritis and cartilage · 2026
A self-perpetuating cycle of Type H vessel proliferation and T-2 induced inflammation drives KBD pathogenesis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wan Xufeng, Du Hao, Zhang Yao, Cai Yongrui, Chen Anjing, Liu Xiaoyang, Su Qiang, Chen Xuming, Du Ze, Chen Yangmengfan, Tang Haiwei, Zhou Xinran, Wang Duan, Zhou Zongke
Аннотация
OBJECTIVE: Kashin-Beck disease (KBD) primarily impairs the epiphyseal plate in children and adolescents, resulting in enlarged bone ends and short stature. Given the abundance of type H vessels in the growing epiphyseal plate, this spatiotemporal correlation prompted us to investigate their potential role in KBD.
METHODS: A rat KBD model was established by feeding T-2 toxin and a low-selenium. Pharmacological modulation of type H vessels was achieved with Roxadustat (promoter) and Halofuginone (inhibitor). Rats were randomly divided into the placebo group (normal), the low-sel + T-2 group (T-2), the low-sel + T-2 + Roxadustat group (T-2 + RD) and the low-sel + T-2 + Halofuginone group (T-2 + HF). Histopathology, immunofluorescence, single-cell RNA sequencing, qPCR, and explants were employed to assess vascular density, T-2 toxin accumulation, inflammatory markers and cartilage integrity.
RESULTS: Roxadustat increased type H vessel density (Mean Difference (MD): 4.11, 95%CI: 0.19, 8.04), amplified T-2 toxin accumulation near the epiphyseal plate (MD: 0.16, 95%CI: 0.062, 0.25) and exacerbated chondrocyte apoptosis and necrosis. Conversely, HF reduced type H vessel proliferation (MD: -3.70, 95%CI: -6.67, -0.73), decreased T-2 toxin levels and suppressed inflammation (MD: -0.17, 95%CI: -0.23, -0.11), while preserving proteoglycan content and cartilage morphology. Single-cell RNA sequencing, qPCR and explants revealed that T-2 toxin-induced inflammation upregulated IL-6 and SELE, promoting type H vessels proliferation.
CONCLUSIONS: This study identifies type H vessels as critical mediators of KBD pathogenesis, linking T-2 toxin transport, inflammation and cartilage damage. The findings highlight a vicious cycle involving type H vessel proliferation and inflammatory signaling.
METHODS: A rat KBD model was established by feeding T-2 toxin and a low-selenium. Pharmacological modulation of type H vessels was achieved with Roxadustat (promoter) and Halofuginone (inhibitor). Rats were randomly divided into the placebo group (normal), the low-sel + T-2 group (T-2), the low-sel + T-2 + Roxadustat group (T-2 + RD) and the low-sel + T-2 + Halofuginone group (T-2 + HF). Histopathology, immunofluorescence, single-cell RNA sequencing, qPCR, and explants were employed to assess vascular density, T-2 toxin accumulation, inflammatory markers and cartilage integrity.
RESULTS: Roxadustat increased type H vessel density (Mean Difference (MD): 4.11, 95%CI: 0.19, 8.04), amplified T-2 toxin accumulation near the epiphyseal plate (MD: 0.16, 95%CI: 0.062, 0.25) and exacerbated chondrocyte apoptosis and necrosis. Conversely, HF reduced type H vessel proliferation (MD: -3.70, 95%CI: -6.67, -0.73), decreased T-2 toxin levels and suppressed inflammation (MD: -0.17, 95%CI: -0.23, -0.11), while preserving proteoglycan content and cartilage morphology. Single-cell RNA sequencing, qPCR and explants revealed that T-2 toxin-induced inflammation upregulated IL-6 and SELE, promoting type H vessels proliferation.
CONCLUSIONS: This study identifies type H vessels as critical mediators of KBD pathogenesis, linking T-2 toxin transport, inflammation and cartilage damage. The findings highlight a vicious cycle involving type H vessel proliferation and inflammatory signaling.